ribosomal protein L13 pseudogene 2Genealiases: RPL13P3 · RPL13_7_1707 · dJ599F21.2
Q-omics provides the consensus-scored RPL13P2 profile across patient tissues and cancer cell-line models. RPL13P2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, RPL13P2 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, RPL13P2 RNA expression shows 12,396 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight OV, COAD, and DLBC as cancer lineages where RPL13P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL13P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL13P2 survival associations across molecular data types. RPL13P2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL13P2 RNA expression–survival associations across cancer types. High RPL13P2 expression shows unfavorable associations in OV, SARC and ACC, but favorable associations in CESC, UCEC and THYM. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify OV as the clearest survival context for RPL13P2 RNA expression.
This table summarizes RPL13P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL13P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL13P2 shows lower tumor expression in BRCA, STAD and PAAD and higher tumor expression in COAD, KIRC and KIRP. The COAD box plot shows higher RPL13P2 RNA expression in tumor versus normal tissue (log2 FC = +2.352, t-test p < 0.001).
This table shows molecular features associated with RPL13P2 in patient tissues and cancer cell lines. In patient samples, RPL13P2 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
